Frauenfeld, 19 August 2025
Press release
Ad hoc announcement pursuant to Art. 53 LR
DocMorris increases Rx revenue by over 40 per cent in the first half of the year and continues to expand its health ecosystem
-
Total revenue rises by 10.2 per cent in the first half of the year
-
Rx growth accelerates to 43.5 per cent; sequential quarterly growth of 4.6 per cent
-
TeleClinic increases revenue by over 150 per cent
-
Continued structural EBITDA improvement in the second quarter
-
AI-based DocMorris Assistant launched as a digital companion
CEO Walter Hess says: “
DocMorris is continuing to develop in a clearly recognisable way: we are consistently strengthening our foundation with the online pharmacy and scaling new, high-growth services in parallel. By expanding our ecosystem, we are laying the foundation to position ourselves as Europe's trusted health companion. A key milestone in this process is the AI-based DocMorris Assistant, which combines our offerings into an integrated, comprehensive healthcare experience for our customers.”
CFO Daniel Wüest adds: “
With our revenue growth in the first half of the year, we are on track to achieve our targets. The financial result improved structurally, particularly in the second quarter, and shows that we are on a clear path to sustainable profitability.”
Significant revenue growth in the first half of the year
-
DocMorris increased its external revenue
[1]
by 10.2 per cent
[2]
to CHF 572.1 million in the first half of the year.
-
Despite fewer working days due to public holidays, revenue rose by 7.1 per cent to CHF 275.5 million in the second quarter.
-
The number of active customers
[3]
rose from 10.3 million to 10.5 million in the first half of the year, with a significant increase in the number of new Rx customers.
Clearly improved result in the second quarter
-
Adjusted EBITDA amounted to minus CHF 28.8 million in the first half of the year.
-
The first quarter included upfront costs for the TV campaign, while the ongoing costs of the campaign are spread across all quarters.
-
The visible structural improvement in EBITDA in the second quarter will continue in the second half of the year.
Rx growth continues to accelerate
-
External Rx revenue rose significantly by 43.5 per cent in the first half of the year.
-
From the first to the second quarter, Rx revenue increased by 4.6 per cent.
-
DocMorris expects sequential growth to accelerate further, driven by an increase in the basket value of existing customers and higher order frequencies.
-
The ruling of the Federal Court of Justice on 17 July 2025 on the admissibility of prescription bonuses (see
press release
) strengthens the competitive position.
Focus on profitability and growth in the non-Rx business
-
In the non-Rx business
[4]
, external revenue increased by 4.4 per cent in the first half of the year, despite the discontinuation of the Zur Rose brand at the end of 2024.
-
The services TeleClinic, retail media and marketplace developed over proportionately well in terms of revenue and EBITDA.
TeleClinic grows strongly
-
TeleClinic recorded growth of over 150 per cent to CHF 11.2 million in the first half of the year.
-
With its rapidly growing number of partnerships, TeleClinic is becoming an integral part of the standard of care in Germany with its leading range of services and products.
-
With Westfalen-Lippe (16,000 physicians), the second cooperation agreement with a regional physician association (KVWL) has been won.
-
Since April 2025, physicians in Germany have been able to carry out and bill up to 50 per cent (previously 30 per cent) of their treatments online.
DocMorris continues to expand its health ecosystem
-
DocMorris offers its customers and patients comprehensive digital services: online pharmacy, marketplace, telemedicine, relevant health content and services.
-
In August, the beta version of the AI-based DocMorris Assistant was launched, which will give patients access to an integrated, comprehensive healthcare experience.
Outlook
-
Based on developments to date, management confirms the revenue and earnings guidance for 2025 and the medium-term targets announced on 10 April.
|
Key financials,
in CHF million (unaudited)
|
|
1.1.-30.6.2025
|
|
1.1.-30.6.2024
|
|
Gross margin in % of net revenue
|
|
22.3%
|
|
21.6%
|
|
Earnings before interest, taxes, depreciation and amortisation adjusted (EBITDA adjusted)
|
|
-28.8
|
|
-20.1
|
|
in % of net revenue
|
|
-5.3%
|
|
-4.1%
|
|
Earnings before interest, taxes, depreciation and amortisation (EBITDA)
|
|
-27.1
|
|
-21.7
|
|
in % of net revenue
|
|
-5.0%
|
|
-4.4%
|
|
Earnings before interest and taxes (EBIT)
|
|
-50.0
|
|
-44.4
|
|
in % of net revenue
|
|
-9.2%
|
|
-8.9%
|
|
Net income / (loss)
|
|
-61.6
|
|
-37.9
|
|
in % of net revenue
|
|
-11.4%
|
|
-7.6%
|
|
|
|
30.6.2025
|
|
31.12.2024
|
|
Equity
|
|
480.4
|
|
340.1
|
|
in % of total assets
|
|
52.9%
|
|
43.7%
|
|
Cash and cash equivalents
|
|
230.3
|
|
95.4
|
|
Active customers,
in million
|
|
10.5
|
|
10.3
|
|
Revenue,
in CHF million (unaudited)
|
1.1.-30.6.2025
|
1.1.-30.6.2024
|
Change
|
|
DocMorris external revenue
|
572.1
|
530.1
|
7.9%
|
|
DocMorris external revenue in local currency
|
|
|
10.2%
|
|
DocMorris
|
541.5
|
496.3
|
9.1%
|
|
DocMorris in local currency
|
|
|
11.5%
|
|
|
|
|
|
|
Markets
|
|
|
|
|
Germany external revenue
|
538.6
|
497.8
|
8.2%
|
|
Germany external revenue in local currency
|
|
|
10.5%
|
|
Germany external revenue Rx
|
109.7
|
78.1
|
40.5%
|
|
Germany external revenue Rx in local currency
|
|
|
43.5%
|
|
Germany external revenue non-Rx
|
428.9
|
419.7
|
2.2%
|
|
Germany external revenue non-Rx in local currency
|
|
|
4.4%
|
|
Germany
|
508.0
|
463.9
|
9.5%
|
|
Germany in local currency
|
|
|
11.9%
|
|
Europe
|
33.5
|
32.3
|
3.5%
|
|
Europe in local currency
|
|
|
5.7%
|
|
Revenue,
in CHF million (unaudited)
|
1.4.-30.6.2025
|
1.4.-30.6.2024
|
Change
|
|
DocMorris external revenue
|
275.5
|
267.7
|
2.9%
|
|
DocMorris external revenue in local currency
|
|
|
7.1%
|
|
DocMorris
|
260.8
|
250.4
|
4.2%
|
|
DocMorris in local currency
|
|
|
8.4%
|
|
|
|
|
|
|
Markets
|
|
|
|
|
Germany external revenue
|
258.5
|
250.7
|
3.1%
|
|
Germany external revenue in local currency
|
|
|
7.3%
|
|
Germany external revenue Rx
|
55.8
|
42.5
|
31.2%
|
|
Germany external revenue Rx in local currency
|
|
|
36.2%
|
|
Germany external revenue non-Rx
|
202.7
|
208.2
|
-2.6%
|
|
Germany external revenue non-Rx in local currency
|
|
|
1.3%
|
|
Germany
|
243.8
|
233.4
|
4.5%
|
|
Germany in local currency
|
|
|
8.7%
|
|
Europe
|
17.0
|
17.0
|
0.0%
|
|
Europe in local currency
|
|
|
3.9%
|
The half-year report and presentation are available on the website as a download
here
(corporate.docmorris.com | Investor Relations | Financial publications).
At 11 a.m. CEST today there will be a conference call in English for analysts and the media.
Speakers: Walter Hess (CEO) and Daniel Wüest (CFO)
To register for the conference call, please use this link:
https://webcast.meetyoo.de/reg/iLlT7NlStAmK
After registration, participants will receive a confirmation e-mail with personal dial-in details.
Please dial in approx. 5 minutes before the conference call begins.
To follow the livestream, please use this link:
https://www.webcast-eqs.com/docmorris-2025-h1
Sound and presentation in the web browser. Participants on the phone please mute the browser sound.
The playback can be viewed after the conference under the same link.
Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10
Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1
Agenda
|
16 October 2025
|
Q3/2025 Trading update
|
|
20 January 2026
|
Sales 2025
|
|
19 March 2026
|
2025 Full-year results and outlook 2026 (conference call/webcast)
|
|
16 April 2026
|
Q1/2026 Trading update
|
|
12 May 2026
|
Annual General Meeting, Zurich
|
|
19 August 2026
|
2026 Half-year results (conference call/webcast)
|
|
15 October 2026
|
Q3/2026 Trading update
|
DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.
[1]
External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.
[2]
All percentages are in local currency.
[3]
Customers supplied by DocMorris, either directly or through its partners.
[4]
Consisting of OTC business and services.